Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company’s DepoVax™-based Programs
Presentation at the 2017
Researchers at the ReSViNET Conference Will Present Data Focused on Immunovaccine’s Novel RSV Target
Preclinical data to be presented at the 2017
Name: “Predicting the efficacy of combination immunotherapy in animal models using tumor microenvironment immune cell profiling.”
Poster Number: P297
Time: 12:30 to
Location: The Gaylord National Hotel & Convention Center in
In addition, clinical study investigators will present a poster related to Immunovaccine’s Phase 1 data evaluating its investigational vaccine candidate, DPX-RSV, at the 4th ReSViNET (Respiratory Syncytial Virus Network) Experts’ Meeting taking place in Malaga,
This poster is entitled “An RSV Vaccine Based on the Small Hydrophobic Ectodomain Protein Presented with a Novel Lipid-Based Adjuvant is Highly Immunogenic and Safe in Adults.” Researchers will discuss the Company’s novel, proprietary target, the SH ectodomain of the RSV virus, and review the strong safety profile and the highly immunogenic responses from DPX-RSV, which endured up to one year from the initial dosing.
Details on the time and location for the ReSViNET poster viewing will be made available on the
DepoVax is Immunovaccine’s proprietary delivery formulation that uses a novel process to present stimulants to the human immune system, and sustain them over time .The technology underlying DepoVax formulations suspends vaccine components in a 100% oil-based diluent that prevents their release at the site of injection. This process forces immune cells to take up these components in an active process, delivering them directly to immune organs such as the lymph nodes. DepoVax formulations have undergone extensive testing in more than 60 preclinical and seven clinical studies. In clinical trials, these formulations have consistently demonstrated the ability to generate robust T and B cell responses, and durable immune responses.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: Immunovaccine Inc.